FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...
Search | FDA - U.S. Food and Drug Administration
FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders....
What to Know About the New Nasal Spray for Tough Depression
3 days ago · The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
Jan 22, 2025 · FDA approves standalone use of J&J’s ketamine-derived depression treatment ... Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused ...
FDA Approves Esketamine as First Monotherapy for Treatment …
Jan 21, 2025 · The US Food and Drug Administration (FDA) approved esketamine (SPRAVATO) CIII nasal spray as the first monotherapy for adults with treatment-resistant depression (TRD), announced by Johnson & Johnson on January 21, 2025. 1. The approval of this supplemental New Drug Application (sNDA) was based on phase 4 randomized, double-blind, multicenter, placebo-controlled study in which esketamine alone ...
Major depression: FDA approves esketamine nasal spray
4 days ago · Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images ...
SPRAVATO® (esketamine) approved in the U.S. as the first and …
Jan 21, 2025 · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to ...
FDA allows standalone use of nasal spray antidepressant Spravato ...
Jan 21, 2025 · The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.
FDA OKs Esketamine Nasal Spray Monotherapy for Depression
6 days ago · The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...
Spravato Nasal Spray Can Now Be Used Alone for Treatment …
2 days ago · Spravato is a form of esketamine that patients take as a self-administered nasal spray under the supervision of a healthcare provider. Esketamine and ketamine are mirror molecules that together form ketamine, a psychoactive drug that is FDA-approved as an anesthetic in emergency medicine.